SAGE

Sage Therapeutics Inc

Healthcare, Event Driven/Special Sit


Presented:04/20/2016
Price:$37.77
Cap:$1.09B
Current Price:$6.86
Cap:$0.42B

Presented

Date04/20/2016
Price$37.77
Market Cap$1.09B
Ent Value$1.49B
P/E RatioN/A
Book Value$6.03
Div Yield0%
Shares O/S28.81M
Ave Daily Vol556,182
Short Int18.13%

Current

Price$6.86
Market Cap$0.42B
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-threatening central nervous system disorders. Its product candidate, SAGE-547, is in clinical development for super-refractory status epilepticus. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Publicly traded companies mentioned herein: SAGE Therapeutics (SAGE)

Highlights

The presenter is short shares of SAGE Therapeutics (SAGE). The bulk of SAGE’s valuation stems from SAGE-547, a seizure drug, but the presenter feels SAGE-547 is not the uniquely differentiated drug it purports to be. In addition, SAGE-547’s total addressable market could be smaller than expected, and clinical trial results are muddier than it appears. If SAGE-547 does not pass Phase 3 testing, SAGE shares could trade down to the cash value of the business since the presenter views the rest of SAGE’s portfolio as too exploratory or early-stage to be valued.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.